Apple polyphenols each day may help keep intestinal inflammation away

Summary: phenolic compounds in apples have beneficial effects for autoimmune inflammatory bowel disease.

A paper just published in the Journal of Leukocyte Biology demonstrates the mechanism by which polyphenols in apples help quell the inflammation of the autoimmune diseases ulcerative colitis and Crohn’s disease. The authors state:

“Human IBD, including UC and Crohn’s disease, is characterized by a chronic, relapsing, and remitting condition that exhibits various features of immunological inflammation and affects at least one/1000 people in Western countries. Polyphenol extracts from a variety of plants have been shown to have immunomodulatory and anti-inflammatory effects. In this study, treatment with APP [apple polyphenols] was investigated to ameliorate chemically induced colitis.”

The authors administered APP to study animals genetically predisposed to autoimmune inflammatory bowel disease win whom inflammation as induced by chemical irritation. Their findings documented an protective effect:

“Oral but not peritoneal administration of APP during colitis induction significantly protected C57BL/6 mice against disease, as evidenced by the lack of weight loss, colonic inflammation, and shortening of the colon. APP administration dampened the mRNA expression of IL-1β, TNF-α, IL-6, IL-17, IL-22, CXCL9, CXCL10, CXCL11, and IFN-γ in the colons of mice with colitis.”

A rational treatment strategy for autoimmune disease requires an assessment of the factors involved in the loss of self-tolerance, including integrity of barrier systems, glutathione production and recycling, nitric oxide synthase production, regulatory T cell function, cytokine regulation, antigenic environmental triggering agents, lifestyle factors that modulate genetic expression, etc. For palliation, however, interventions that can reduce inflammation without side effects are desirable. Although an extract concentrates polyphenols more than is obtained by eating apples, compounds like this and resveratrol are worthy of consideration for adjunctive use. The authors conclude:

“…these results show that oral administration of APP protects against experimental colitis and diminishes proinflammatory cytokine expression via T cells.”

Persistent gastrointestinal symptoms demand a look at the brain-gut axis

Assuming that gross pathologies, infections and dietary imprudence have been ruled out, persistent gastrointestinal symptoms require an assessment of the brain-gut axis. More than ever before, research is revealing the profound degree to which gastrointestinal function and even tissue integrity depend on brain output. A spate of earlier reports emphasized the abnormal brain response to sensory signals received from the gut, as in a paper published in Gastroenterology Clinics of North America. The author states:

“Functional neuroimaging studies have demonstrated evidence of altered regional brain activation responses during visceral and somatic stimuli in IBS [irritable bowel syndrome]…Altered brain responses in IBS, particularly to visceral stimuli, include activation of regions concerned with attentional processes and response selection, corticolimbic regions concerned with emotional and autonomic responses to stimuli, and subcortical regions receiving cortical projections from the latter and afferent input from the soma [body] and viscera [organs].”

And remarkably…

Altered activations of these regions also may be present [even] in the absence of a noxious visceral stimulus.

A further indication of the relevance of these observations is that…

“Changes in rCBF [regional cerebral blood flow, a metric for brain function] of some of these regions have been associated with treatment response in IBS.”

As in so many other clinical conditions, loss of cortical inhibitory function—the brain’s great task of calming or attenuating incoming signals—is suggested here:

“A plausible hypothesis for the observations from brain imaging studies is that IBS patients demonstrate a compromised activation of pain inhibition circuits including those of the cortico-pontine circuit but increased activation of limbic and paralimbic circuits that may be related to pain facilitation.”

The authors of a study published in the American Journal of Gastroenterology come to a similar conclusion. Importantly, they also note an association with fibromyalgia:

“Symptoms of irritable bowel syndrome (IBS) and fibromyalgia (FM) commonly coexist. We hypothesized that one of the mechanisms underlying this comorbidity is increased activation of brain regions concerned with the processing and modulation of visceral and somatic afferent information, in particular subregions of the anterior cingulate cortex (ACC).”

With their data they were able to discriminate between IBS and IBS + fibromyalgia in the modulation of brain responses to stimuli:

“”Whereas the somatic stimulus was less unpleasant than the visceral stimulus for IBS patients without FM, the somatic and visceral stimuli were equally unpleasant in the IBS + FM group…There was a greater rCBF increase in response to noxious visceral stimuli in IBS patients and to somatic stimuli in IBS + FM patients.”

Thus the authors conclude that exaggerated brain responses to peripheral stimuli play a role in both IBS and FM. In this context ‘cognitive enhancement’ means inhibition failure:

Chronic stimulus-specific enhancement of ACC responses to sensory stimuli in both syndromes may be associated with cognitive enhancement of either visceral (IBS) or somatic (IBS + FM) sensory input and may play a key pathophysiologic role in these chronic pain syndromes.”

Brain control of the immune system in the gut and disturbances in neuroimmune regulation that persist long after an initial insult such as GI infection are discussed in a paper just published in Nature Reviews Gastroenterology & Hepatology. The authors state:

IBS is one of the most common functional gastrointestinal disorders worldwide and is thought to be the result of disturbed neural function along the brain–gut axis…important roles for low-grade inflammation and immunological alterations in the development of symptoms compatible with IBS have become evident.”

As in so many other varied conditions and chronic pain syndromes, disturbance of the regulatory loop between the brain and periphery becomes the cause of chronic symptoms even long after the initial insult has resolved:

“The development of long-standing gastrointestinal symptoms after infectious gastroenteritis and patients with IBD [inflammatory bowel disease] in remission frequently having functional gastrointestinal symptoms support this hypothesis.”

Loss of the barrier function of the lining of the intestine that separates its contents from the surrounding immune tissue—abnormal intestinal permeability—is a key feature of brain-gut neuroimmune dysfunction.

“In addition, studies have demonstrated that IBS may be associated with an activated adaptive immune response. Increased epithelial barrier permeability and an abnormal gut flora might lead to increased activation of the intestinal immune system. Functional and anatomical evidence for abnormal neuroimmune interactions has been found in patients with IBS.

Clinicians and patients alike with experience of complaints associated with intestinal permeability appreciate how vexing a problem this can be to manage. A fascinating paper published in the Journal of Neurotrauma sheds light on the usually overlooked yet critical role of the brain in maintaining and repairing the gut lining. The authors state:

Traumatic brain injury (TBI) can lead to several physiologic complications including gastrointestinal dysfunction. Specifically, TBI can induce an increase in intestinal permeability, which may lead to bacterial translocation, sepsis, and eventually multi-system organ failure.”

They examined animals subject to TBI for expression of the zonulin [ZO-1] and occludin, proteins critical for integrity of the intestinal lining, to determine if they decreased following TBI. They also looked for a subsequent increase in intestinal permeability. What did their data show?

TBI caused a significant increase in intestinal permeability compared to sham animals 6 h after injury. Expression of ZO-1 was decreased by 49% relative to sham animals, whereas expression of occludin was decreased by 73% relative to sham animals.”

This has great clinical significance: brain output is critical for maintenance of the intestinal epithelium. The authors conclude:

An increase in intestinal permeability corresponds with decreased expression of tight junction proteins ZO-1 and occludin following TBI. Expression of intestinal tight junction proteins may be an important factor in gastrointestinal dysfunction following brain injury.”

A paper published in the Journal of Physiology and Pharmacology describes one effect of disturbance of the brain-gut axis as an increase in visceral sensitivity. The authors note:

“Chronic abdominal pain is the most distressing symptom in patients with functional digestive disorders (FDD)…a chronic visceral hyperalgesia, in the absence of detectable organic disease, is implicated…Several lines of evidence suggest a strong modulatory or etiologic role of the central nervous system in the pathophysiology of IBS…These findings were consistent with an IBS model that includes both the exaggerated activation of a vigilance network (dorsolateral PFC) and a failure in pain inhibition network anterior cingulate cortex (ACC).”

They report their findings on using fMRI (functional magnetic resonance imaging) to characterize the areas of the brain activated by rectal distension in healthy volunteers and compared them with the activation patterns in a population of IBS patients. In the latter…

“…we did not observe any neuronal activation in locations activated in healthy volunteers (ACC [anterior cingulate cortex], dorsolateral PFC) while a significant deactivation was observed in the IC [insular cortex] and in the amygdala, a limbic structure with a role to assign emotional significance to a current experience related to anxiety and fear. Brain imaging techniques thus appear as useful tools to characterize normal and abnormal brain processing of visceral pain in patients with FDD.”

Another study published recently in the same journal reported on the brain’s output for stimulating the production of pancreatic digestive enzymes:

Brain is also implicated in the regulation of pancreatic exocrine function. Dorsal vagal complex of the brainstem (DVC) appears the center of long vago-vagal cholinergic entero-pancreatic reflex.”

It is of great practical importance for clinicians to bear in mind that the immune system is part of the brain-gut axis, and that there is a bi-directional communication between the enteric nervous and immune systems in the gut and the brain. Naturally brain-gut regulation is also influenced by emotion and cognition. A review just published in the journal Brain, Behavior and Immunity offers an aerial perspective:

“The role of central nervous system mechanisms along the “brain-gut axis” is increasingly appreciated, owing to accumulating evidence from brain imaging studies that neural processing of visceral stimuli is altered in IBS together with long-standing knowledge regarding the contribution of stress and negative emotions to symptom frequency and severity.”

Regarding the role of the immune system:

“At the same time, there is also growing evidence suggesting that peripheral immune mechanisms and disturbed neuro-immune communication could play a role in the pathophysiology of visceral hyperalgesia.”

The authors also assert that the higher level of “top-down” regulation must be considered:

“…recent advances in research on the pathophysiology of visceral hyperalgesia…support that in addition to lower pain thresholds displayed by a significant proportion of patients, the evaluation of pain appears to be altered…Disturbed “top-down” emotional and cognitive pain modulation in IBS is reflected by functional and possibly structural brain changes involving prefrontal as well as cingulate regions.”

And, of course, it’s a ‘two-way street’—disturbed immune and neural signalling go the other way too:

“At the same time, there is growing evidence linking peripheral and mucosal immune changes and abdominal pain in IBS, supporting disturbed peripheral pain signalling. Findings in post-infectious IBS emphasize the interaction between centrally-mediated psychosocial risk factors and local inflammation in predicting long-term IBS symptoms.”

The authors of a paper published in Gastroentérologie Clinique et Biologique also comment on this two-way channel:

There is a bidirectional relation between the central nervous system and the digestive tract, i.e., the brain-gut axis. Numerous data argue for a dysfunction of the brain-gut axis in the pathophysiology of irritable bowel syndrome (IBS). Visceral hypersensitivity is a marker of IBS as well as of an abnormality of the brain-gut axis. This visceral hypersensitivity is peripheral and/or central in origin and may be the consequence of digestive inflammation or an anomaly of the nociceptive [pain-sensing] message treatment at the spinal and/or supraspinal level.”

Importantly, brain-gut axis dysregulation is also expressed through the autonomic (sympathetic and parasympathetic) nervous system…

Disturbances of the autonomic nervous system are observed in IBS as a consequence of brain-gut axis dysfunction.”

A study published in the journal Neurology offers additional evidence that the brain is a key component of chronic gastrointestinal and other chronic pain disorders . The authors recognize the link between this and fibromyalgia:

“Abnormal cortical pain responses in patients with fibromyalgia and conversion disorder raise the possibility of a neurobiologic basis underlying so-called “functional” chronic pain.”

They used fMRI (functional MRI) to examine the brains of healthy subjects and those with IBS while stimulating with rectal distension. Their experiences with pain or urging were correlated with the fMRI data. There was a clear difference between the IBS and normal subjects:

“In IBS, abnormal responses associated with rectal-evoked sensations were identified in five brain regions. In primary sensory cortex, there were urge-related responses in the IBS but not control group. In the medial thalamus and hippocampus, there were pain-related responses in the IBS but not control group.”

The authors concluded:

“Percept-related fMRI revealed abnormal urge- and pain-related forebrain activity during rectal distension in patients with irritable bowel syndrome (IBS)…abnormal brain responses in IBS may reflect the sensory symptoms of rectal pain and hypersensitivity, visceromotor dysfunction, and abnormal interoceptive processing.”

The authors of another paper published in Gastroentérologie Clinique et Biologique came to similar conclusions regarding the interactions of the brain, immune system and higher functions. [For lay readers of this post: the enteric nervous system (the 'brain in the gut') is part of the autonomic nervous system that regulates all visceral functions including those in the gut].

“Hypersensitivity is due either to an afferent neurons dysfunction at the enteric nervous system level, either to an abnormal brain-gut axis processing of sensory or nociceptive inputs arising from the gut, at the spinal or supraspinal level. Disturbances of the autonomic nervous system occur in IBS as a consequence of this brain-gut axis dysfunction.”

Moreover…

“Neurological abnormalities may be triggered by inflammation, mast cell [a type of immune cell] dysfunction or increased intestinal permeability while the neuro-immune consequences of stress (mainly chronic) play a major role…”

And of course…

“The role of emotions and mood disturbances cannot be omitted in the interpretation the central processing of digestive sensory inputs. Neurosciences, in particular brain imaging techniques, have contributed to this better understanding of irritable bowel syndrome pathophysiology.”

A study published in The Journal of Neuroscience demonstrates how anticipation can affect brain regions that function to regulate sensory signals coming from the gut:

“Cognitive factors such as fear of pain and symptom-related anxiety play an important role in chronic pain states. The current study sought to characterize abnormalities in preparatory brain response before aversive pelvic visceral distention in irritable bowel syndrome (IBS) patients and their possible relationship to the consequences of distention.”

They too used brain fMRI to examine the differences in response to rectal distention between IBS patients and healthy controls. Their data showed marked differences in the ability to activate brain areas responsible for anticipatory calming and for inhibition of sensory signals coming from the intestines during distention:

“During cued anticipation of distention, activity decreased in the insula, supragenual anterior cingulate cortex (sACC), amygdala, and dorsal brainstem (DBS) of controls. IBS patients showed less anticipatory inactivation…During subsequent distention, both groups showed activity increases…[relevant brain areas]…The increases were more extensive in patients, producing significant group differences in dorsal ACC and DBS.”

The authors conclude that diminished inhibitory function may result in a heightened sensitivity to sensations from the gut:

“Deficits in preparatory inhibition of DBS, including the locus ceruleus complex and parabrachial nuclei, may interfere with descending corticolimbic inhibition and contribute to enhanced brain responsiveness and perceptual sensitivity to visceral stimuli in IBS.”

A subsequent study published in the journal GUT, An International Journal of Gastroenterology and Hepatology specifically examines the effect of anxiety and depression on the central nervous system processing of visceral stimuli. The authors set out to…

“…address the role of anxiety and depression symptoms in altered pain processing in irritable bowel syndrome (IBS).

They too used fMRI to compare patients with IBS to normal controls for the experience of pain or discomfort in correlation with brain activation. As before the data told an unambiguous story:

“Anxiety symptoms in IBS were significantly associated with pain-induced activation of the anterior midcingulate cortex and pregenual anterior cingulate cortex. Depression scores correlated with activation of the prefrontal cortex (PFC) and cerebellar areas within IBS. Group comparisons with the two-sample t test revealed significant activation in the IBS versus controls contrast in the anterior insular cortex and PFC.”

This is certainly not earth-shaking news, but it does objectively show how anxiety and depression can affect brain function in such a way that visceral stimuli are permitted to bombard the senses abnormally:

Altered central processing of visceral stimuli in IBS is at least in part mediated by symptoms of anxiety and depression, which may modulate the affective–motivational aspects of the pain response.

The authors of a review published in Psychopharmacology document how the stress of maternal separation can cause brain-gut axis dysfunction. Referring to early life stress they state…

“…stress during this critical period also induces alterations in many systems throughout the body…Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is thought to involve a dysfunctional interaction between the brain and the gut. Essential aspects of the brain–gut axis include spinal pathways, the hypothalamic pituitary adrenal axis, the immune system, as well as the enteric microbiota. Accumulating evidence suggest that stress, especially in early life, is a predisposing factor to IBS.”

Having reviewed the relevant data, they…

“…describe the components of the brain–gut axis individually and how they are altered by maternal separation. The separated phenotype is characterised by alterations of the intestinal barrier function, altered balance in enteric microflora, exaggerated stress response and visceral hypersensitivity…”

What are practitioners to make of all this when endeavoring to help someone with a chronic gastrointestinal complaint? Having investigated for gross pathologies, infections, and food allergies or intolerances, the science indicates that we must accept the role of the brain-gut axis in enteric immune function, maintaining the gut epithelium, and regulating digestive function and sensory phenomena. The brain-gut axis, like all sentient biological entities, is an emergent system. A quote from David Brooks writing in the New York Times offers a working definition:

Emergent systems are ones in which many different elements interact. The pattern of interaction then produces a new element that is greater than the sum of the parts, which then exercises a top-down influence on the constituent elements…Emergent systems are bottom-up and top-down simultaneously. They have to be studied differently, as wholes and as nested networks of relationships.”

Realistically, case management of brain-gut axis disorders requires attending to the multiple factors that influence brain function (a brief overview is available as the Parents’ Guide To Brain Health; it pertains equally to adults). Bottom-up and top-down simultaneously in this case implies that the physiological capacity of the brain to inhibit and stimulate appropriately, and cognition/emotion, are given equal treatment with the condition of the gut microbial ecology and factors that may promote a local inflammatory response. A full treatment of this topic is at least a weighty volume, but there are some recent reports of practical clinical significance on centrally acting therapies for the brain-gut axis worth mentioning in this context. The authors of a paper published in Gastroenterology Clinics of North America state:

“Irritable bowel syndrome (IBS) and other functional gastrointestinal (GI) disorders typically defy traditional diagnostic methods based on structural abnormalities, and has led to the emergence of the discipline of neurogastroenterology or the study of the “brain-gut axis,” which is based on dysregulation of neuroenteric pathways as a key pathophysiological feature of IBS. Centrally acting treatments can influence these pathways and improve the clinical manifestations of pain and bowel dysfunction associated with this disorder. To successfully implement these treatment strategies, it is important to recognize their dual effects on brain and gut…

In this respect we can appreciate the key role of the autonomic nervous system since there are practical ways to objectively evaluate ANS function in an office-based practice (heart rate variability analysis) and non-invasive therapies that modulate the brain and ANS through sensory-based peripheral modalities (all kinds of peripheral stimuli applied to elicit a corrective central response). The author of a paper published recently in La revue de médecine interne notes:

“Our digestive tract has an autonomous functioning but also has a bidirectional relation with our brain known as brain-gut interactions. This communication is mediated by the autonomous nervous system, i.e., the sympathetic and parasympathetic nervous systems, with a mixed afferent and efferent component, and the circumventricular organs located outside the blood-brain barrier. The vagus nerve, known as the principal component of the parasympathetic nervous system…has also anti-inflammatory properties both through the hypothalamic pituitary adrenal axis (through its afferents) and the cholinergic anti-inflammatory pathway (through its efferents). The sympathetic nervous system has a classical antagonist effect on the parasympathetic nervous system at the origin of an equilibrated sympathovagal balance in normal conditions.”

This invites another look at an earlier post documenting the anti-inflammatory role of the parasympathetic nervous system and the use of heart rate variability analysis to objectively evaluate its function. The ANS is the neural communicating channel between the brain and the gut, offering therapeutic access to both…

“The brain is able to integrate inputs coming from the digestive tract inside a central autonomic network organized around the hypothalamus, limbic system and cerebral cortex (insula, prefrontal, cingulate) and in return to modify the autonomic nervous system and the hypothalamic pituitary adrenal axis in the frame of physiological loops. A dysfunction of these brain-gut interactions, favoured by stress, is most likely involved in the pathophysiology of digestive diseases such as irritable bowel syndrome or even inflammatory bowel diseases. A better knowledge of these brain-gut interactions has therapeutic implications in the domain of pharmacology, neurophysiology, behavioural and cognitive management.”

This gives us background to appreciate a fascinating study published recently in The Journal of Trauma—Injury Infection & Critical Care offering evidence that ANS, specifically vagal, stimulation can prevent the loss of intestinal barrier function associated with traumatic brain injury. The authors state:

“Traumatic brain injury (TBI) causes gastrointestinal dysfunction and increased intestinal permeability. Regulation of the gut barrier may involve the central nervous system. We hypothesize that vagal nerve stimulation prevents an increase in intestinal permeability after TBI.”

They subjected their study animals to TBI after a selected cohort had undergone electrical stimulation of the cervical vagus nerve. They subsequently measured intestinal permeability, tumor necrosis factor-α (an inflammatory cytokine) and, very interestingly, glial fibrillary acidic protein (GFAP) which is a marker of enteric glial activity. What did they find?

“TBI increased intestinal permeability compared with sham…Vagal stimulation prevented TBI-induced intestinal permeability. TBI animals had an increase in intestinal tumor necrosis factor-α 6 hours after injury compared with vagal stimulation + TB…intestinal GFAP was 18.0-fold higher at 4 hours compared with sham and 1.6-fold higher than TBI alone.”

This has profound and practical clinical implications:

“In a mouse model of TBI, vagal stimulation prevented TBI-induced intestinal permeability. Furthermore, vagal stimulation increased enteric glial activity and may represent the pathway for central nervous system regulation of intestinal permeability.”

A paper published last summer in the Journal of Neurogastroenterology and Motility offers one example of a sensory-based peripheral modality that has a therapeutic effect on these central processes, in this case electroacupuncture.

“We evaluated the effect of acupuncture in treating visceral hyperalgesia in an animal model.”

The authors applied either electroacupuncture (EA) or sham acupuncture at acupoint ST-36 to rats with prior neonatal maternal separation stress. The day after the acupuncture treatment they were subject to colorectal distension, comparing them for pain threshold and visceromotor response. They also measured serotonin and Fos expression by immunohistochemistry in the colon, brainstem and spinal cord.

“Rats in EA group had significantly higher pain threshold compared to those in sham acupuncture group…They also had lower visceromotor response as measured by electromyogram compared to those received sham acupuncture at all colorectal distension pressures.”

Electroacupuncture is one of a number of ways to simulate the brain through sensory pathways. In this study the authors concluded:

“Electro acupuncture attenuates visceral hyperlagesia through down-regulation of central serotonergic activities in the brain-gut axis.”

My heart goes out to these study animals, but we can accept the further evidence presented in another paper published recently in The Journal of Trauma—Injury Infection & Critical Care. In this study the authors demonstrated repair of the gut barrier through vagal stimulation after abnormal intestinal permeability induced by burn trauma:

“Severe injury can cause intestinal permeability through decreased expression of tight junction proteins, resulting in systemic inflammation. Activation of the parasympathetic nervous system after shock through vagal nerve stimulation is known to have potent anti-inflammatory effects…We postulated that vagal nerve stimulation improves intestinal barrier integrity after severe burn through an efferent signaling pathway, and is associated with improved expression and localization of the intestinal tight junction protein occludin.”

The authors subjected their animals to burn injury after vagal nerve stimulation for 10 minutes. A separate underwent abdominal vagotomy before vagal nerve stimulation and burn. Intestinal barrier injury, histology, and changes in occludin expression were then assessed. The results were striking…

“Cervical vagal nerve stimulation decreased burn-induced intestinal permeability to FITC-dextran, returning intestinal permeability to sham levels. Vagal nerve stimulation before burn also improved gut histology and prevented burn-induced changes in occludin protein expression and localization. Abdominal vagotomy abrogated the protective effects of cervical vagal nerve stimulation before burn, resulting in gut permeability, histology, and occludin protein expression similar to burn alone.”

Improving parasympathetic function in general and vagal function in particular is of paramount importance in the management of most chronic disorders. The authors conclude:

Vagal nerve stimulation performed before injury improves intestinal barrier integrity after severe burn through an efferent signaling pathway and is associated with improved tight junction protein expression.

Actual case management of brain-gut axis disorders merits an entire textbook, but this can be borne in mind: diet, supplements, medicines, etc. are not enough—good gut function requires good brain output and autonomic regulation. Clinicians actively treating these conditions who are interested in how we apply functional testing for GI inflammation, infection, gut permeability, allergy, ANS function, the brain and brain-gut axis, etc.; and the various therapies brought to bear on the findings; are welcome to contact Lapis Light for collegial conversation.

 

IBS aetiology is most likely multi-factorial involving biological, psychological and social factors. Visceral hyperalgesia (or hypersensitivity) and visceral hypervigilance, which could be mediated by peripheral, spinal, and/or central pathways, constitute key concepts in current research on pathophysiological mechanisms of visceral hyperalgesia. The role of central nervous system mechanisms along the “brain-gut axis” is increasingly appreciated, owing to accumulating evidence from brain imaging studies that neural processing of visceral stimuli is altered in IBS together with long-standing knowledge regarding the contribution of stress and negative emotions to symptom frequency and severity. At the same time, there is also growing evidence suggesting that peripheral immune mechanisms and disturbed neuro-immune communication could play a role in the pathophysiology of visceral hyperalgesia. This review presents recent advances in research on the pathophysiology of visceral hyperalgesia in IBS, with a focus on the role of stress and anxiety in central and peripheral response to visceral pain stimuli. Together, these findings support that in addition to lower pain thresholds displayed by a significant proportion of patients, the evaluation of pain appears to be altered in IBS. This may be attributable to affective disturbances, negative emotions in anticipation of or during visceral stimulation, and altered pain-related expectations and learning processes. Disturbed “top-down” emotional and cognitive pain modulation in IBS is reflected by functional and possibly structural brain changes involving prefrontal as well as cingulate regions. At the same time, there is growing evidence linking peripheral and mucosal immune changes and abdominal pain in IBS, supporting disturbed peripheral pain signalling. Findings in post-infectious IBS emphasize the interaction between centrally-mediated psychosocial risk factors and local inflammation in predicting long-term IBS symptoms. Investigating afferent immune-to-brain communication in visceral hyperalgesia as a component of the sickness response constitutes a promising future research goal.

Antibiotic use can promote inflammatory bowel disease in childhood

The use of antibiotics demands great care and discrimination. A paper just published in Gut, An International Journal of Gastroenterology & Hepatology offers further evidence that disruption of the microbial ecology can promote autoimmune disorders. The authors state:

“The composition of the intestinal microflora has been proposed as an important factor in the development of inflammatory bowel diseases (IBD). Antibiotics have the potential to alter the composition of the intestinal microflora. A study was undertaken to evaluate the potential association between use of antibiotics and IBD in childhood.”

They examined all Danish singleton children born from 1995 to 2003 (577,627 children) for correlations between antibiotic prescriptions and IBD while taking into consideration potential confounding variables. They then calculated rate ratios (RRs) of IBD according to antibiotic use. Their data painted a compelling picture:

“IBD was diagnosed in 117 children during 3,173,117 person-years of follow-up. The RR of IBD was 1.84 for antibiotic users compared with non-users. This association appeared to be an effect on Crohn’s disease (CD) alone (RR 3.41) and was strongest in the first 3 months following use (RR 4.43) and among children with ≥7 courses of antibiotics (RR 7.32).”

In other words, there was an 84% increase in IBD for antibiotic users versus non-users. The increase in Crohn’s disease was particularly dramatic—341% in general, 443% in the first 3 months after antibiotic use, and a whopping 732% for children who had seven or more courses of antibiotics. The authors conclude:

Antibiotic use is common in childhood and its potential as an environmental risk factor for IBD warrants scrutiny. This is the first prospective study to show a strong association between antibiotic use and CD in childhood.”

While, as the authors concede, an observational study does not establish causality, prudence dictates that care be taken in evaluating each patient for propensities to autoimmune disorders, and to apply appropriate pro- and prebiotic support during and after antimicrobial therapy.

Therapeutic resources for inflammatory bowel disease

Autoimmune disease in general and inflammatory bowel disease in particular arise from a constellation of causes that should be investigated and addressed on an individual basis. Nonetheless, methods that calm the inflammatory cascade (without harmful side-effects) are important practical tools. As forthcoming posts will describe in greater detail, nitric oxide production is a critical step in the production of damaging inflammation. A paper published in the European Journal of Clinical Investigation highlights this fact:

Nitric oxide (NO) production, as detectable by indirect and direct methods, as well as the expression of inducible nitric oxide synthase (iNOS) in the intestinal mucosa appear to be enhanced in active ulcerative colitis and, when in excess, to play a proinflammatory role in the disease. Despite some conflicting data, there is evidence that NO production is also increased in Crohn’s disease. Many inflammatory features of inflammatory bowel disease are in keeping with the physiological properties of NO…”

And of interest for clinical case managment…

“The drugs currently used in the treatment of inflammatory bowel disease (steroids, salicylates) do not seem to exert substantial effects on intestinal NO synthesis.”

A study published in the British Journal of Pharmacology examines the ability of the natural flavonoid quercitrin (related to quercitin) to inhibit production of iNOS (‘inducible nitric oxide synthase, the ‘bad’ nitric oxide producing enzyme). The authors state:

Quercitrin, 3-rhamnosylquercetin, is a bioflavonoid with antioxidant properties, which exerts anti-inflammatory activity in experimental colitis. In the present study, different in vivo experiments were performed in order to evaluate the mechanisms of action involved in this effect, with special attention to its effects on proinflammatory mediators, including nitric oxide (NO).”

They examined the effects of quercitrin on inflammation of the intestinal mucosa (‘lining’) induced by DSS (dextran sodium sulfate) both preventatively and, in another cohort, on already established colitis. The results were significant:

“Oral treatment of quercitrin…ameliorated the evolution of the inflammatory process induced when administered in a preventative dosing protocol…on established colitis, it facilitated the recovery of the inflamed mucosa…The beneficial effects exerted by quercitrin were evidenced both histologically and biochemically, and were associated with an improvement in the colonic oxidative status…”

Regarding the role of NO and inflammatory bowel disease…

“…a reduction of colonic NO synthase activity was observed, probably related to a decreased expression in the inducible form of the enzyme [iNOS] via downregulation in the colonic activity of the nuclear factor-κB.”

The authors discuss their findings in summary:

“During the last decade, it has become increasingly clear that NO overproduction by iNOS is deleterious to intestinal function…thus contributing significantly to gastrointestinal immunopathology…the results obtained in the present study reveal that colonic inflammation is associated with a higher colonic NOS activity, mainly attributed to an increase in iNOS expression…the effect showed by quercitrin is most probably related to an inhibition of the expression of this enzyme, which is upregulated as a consequence of the colonic inflammatory process…The antioxidant and/or scavenging properties ascribed to this flavonoid could also contribute to its intestinal anti-inflammatory effect…”

A study published in the European Journal of Immunology sheds more light on the use of quercitin for inflammatory bowel disease. Examining the relationship between quercitrin and quercitin, the authors find…

“…that the in vivo effects of quercitrin…can be mediated by the release of quercetin generated after glycoside’s cleavage by the intestinal microbiota. This is supported by the fact that quercetin, but not quercitrin, is able to down-regulate the inflammatory response of bone marrow-derived macrophages in vitro.”

They also describe evidence for the effect of quercitin on iNOS and the the NF-κB pathway:

“Moreover, we have demonstrated that quercetin inhibits cytokine and inducible nitric oxide synthase expression through inhibition of the NF-κB pathway…(both in vitro and in vivo). As a conclusion, our report suggests that quercitrin releases quercetin in order to perform its anti-inflammatory effect…”

A paper published in the journal Digestive Diseases examines the ability of quercitin to help repair the gut barrier in inflammatory bowel disease. Regarding the intestinal epithelial barrier (‘lining’) the authors state:

In inflammatory bowel disease (IBD), epithelial barrier function is impaired contributing to diarrhea by a leak flux mechanism and perpetuating inflammation by an increased luminal antigen uptake. This barrier of the intestinal epithelium is composed of the apical enterocyte membrane and the epithelial tight junction (TJ) and can be affected by TJ alterations, induction of epithelial apoptoses and appearance of gross lesions like erosions or ulcers as well as by accelerated transcytotic antigen uptake.”

They note that in addition to therapies that oppose Th1 cytokine activity in Crohn’s disease  and Th2 cytokine activity in ulcerative colitis, other agents have been shown to improve barrier function:

“…zinc has been shown to improve barrier function in CD, although the inherent mechanisms are unknown. Finally, food components can strengthen the epithelial barrier as for example the flavonoid quercetin which has been shown to upregulate claudin-4 within the epithelial TJ.”

Curcumin (extracted from the yellow spice turmeric) should also be considered in the functional management of inflammatory bowel disease. The authors of a study published in the journal Inflammatory Bowel Diseases observe:

“Neutrophils (PMN) are the first cells recruited at the site of inflammation. They play a key role in the innate immune response by recognizing, ingesting, and eliminating pathogens and participate in the orientation of the adaptive immune responses. However, in inflammatory bowel disease (IBD) transepithelial neutrophil migration leads to an impaired epithelial barrier function, perpetuation of inflammation, and tissue destruction via oxidative and proteolytic damage. Curcumin (diferulolylmethane) displays a protective role in mouse models of IBD and in human ulcerative colitis, a phenomenon consistently accompanied by a reduced mucosal neutrophil infiltration.”

They investigated the phenomenon of neutrophil modulation by curcumin in vitro and in vivo. Their accumulated data demonstrated that…

“Curcumin attenuated lipopolysaccharide (LPS)-stimulated expression and secretion of macrophage inflammatory protein (MIP)-2, interleukin (IL)-1β, keratinocyte chemoattractant (KC), and MIP-1α in colonic epithelial cells (CECs) and in macrophages. Curcumin significantly inhibited PMN chemotaxis against MIP-2, KC, or against conditioned media from LPS-treated macrophages or CEC, a well as the IL-8-mediated chemotaxis of human neutrophils. At nontoxic concentrations, curcumin inhibited random neutrophil migration, suggesting a direct effect on neutrophil chemokinesis.”

In other words, curcumin was shown to significantly attenuate proinflammatory cytokine expression and white blood cell ‘attack movements’. Thus the authors conclude:

“Our results indicate that curcumin interferes with colonic inflammation partly through inhibition of the chemokine expression and through direct inhibition of neutrophil chemotaxis and chemokinesis.”

A double-blind, placebo-controlled trial of curcumin for the treatment of ulcerative colitis was reported in the journal Clinical Gastroenterology and Hepatology. The authors state:

“Curcumin is a biologically active phytochemical substance present in turmeric and has pharmacologic actions that might benefit patients with ulcerative colitis (UC). The aim in this trial was to assess the efficacy of curcumin as maintenance therapy in patients with quiescent ulcerative colitis (UC).”

They divided a cohort of 89 patients with quiescent UC into a treatment group of 45 who added 1 gram of curcumin taken two times per day to their usual therapy. The other 44 got a placebo.  After 6 months the relapse percentages were 4.65% for those who received curcumin and 20.51% for the placebo group.

“Furthermore, curcumin improved both CAI [clinical activity index] and EI [endoscopic index], thus suppressing the morbidity associated with UC.”

The authors conclude:

Curcumin seems to be a promising and safe medication for maintaining remission in patients with quiescent UC. Further studies on curcumin should strengthen our findings.”

It’s also worth noting a paper published in the journal Current Pharmaceutical Design examines the multiple anti-inflammatory effects of curcumin. The authors first state:

Inflammatory bowel disease (IBD) is a chronic relapsing-remitting condition that afflicts millions of people throughout the world and impairs their daily functions and quality of life… it appears to be driven by inflammatory cytokines such as tumor necrosis factor (TNF)-α. Hence, there is a strong interest in agents that can block the generation or actions of inflammatory cytokines.”

They note that earlier research has demonstrated that curcumin inhibits inflammation through action on cyclooxygenases 1, 2 (COX-1, COX-2), lipoxygenase (LOX), TNF-α, interferon γ (IFN-γ), inducible nitric oxide synthase (iNOS), and the transcriptional nuclear factor kappa B (NF-κB, a key factor in the production of proinflammatory cytokines), and has a strong anti-oxidant effect.

“Therefore, in recent years, the efficacy of curcumin has been investigated in several experimental models of IBD. The results indicate striking suppression of induced IBD colitis and changes in cytokine profiles…”

And in an early successful human IBD study..

“…patients were given curcumin (360mg/dose) 3 or 4 times/day for three months. Further, curcumin significantly reduced clinical relapse in patients with quiescent IBD.”

While it’s difficult to predict ahead of time which patients will have the best response to agents such as curcumin and quercitin, since they are so safe and wholesome we can welcome the authors’ conclusion:

The inhibitory effects of curcumin on major inflammatory mechanisms like COX-2, LOX, TNF-α, IFN-γ, NF-κB and its unrivaled safety profile suggest that it has bright prospects in the treatment of IBD.”

The autoimmune aspect of cardiovascular disease and Th17/Treg imbalance

Clinical ImmunologyCardiovascular disease, an inflammatory disorder, is a leading cause of death and the autoimmune component is one of the most important and in general practice, overlooked, aspects. Consider this paper published not long ago in the journal Clinical Immunology. As the authors state,

Atherosclerosis is a chronic inflammatory disease regulated by T lymphocyte subsets.” ['T lymphocyte subsets' refers to the different categories of lymphocytes that participate in immune reactions.]

Regulatory T cells (Treg) ‘referee’ the immune response and quiet inflammation. Vitamin D is necessary for their production. Th1 refers to the lymphocytes that express the ‘innate’, cell-mediated aspect of the immune response; Th2 is the ‘adaptive’, humoral (antibody) mediated aspect. Th17 cells are a more recently recognized subtype that play a potent role in the immune system’s inflammatory attack.

“Recently, CD4+CD25+Foxp3+ regulatory T (Treg) cells and Th17 cells have been described as two distinct subsets from Th1 and Th2 cells and have the opposite effects on autoimmunity. Th17/Treg balance controls inflammation and may be important in the pathogenesis of plaque destabilization and the onset of acute coronary syndrome [ACS, including unstable angina (UA) and acute myocardial infarction (AMI)].”

The authors investigated this by assessing Th17/Treg functions by cell numbers, related cytokine secretion and their  transcription factors in patients suffering from heart attacks, angina and control subjects free of heart disease. Their data made a strong impression:

“The results demonstrated that patients with ACS revealed significant increase in peripheral Th17 number, Th17 related cytokines (IL-17, IL-6 and IL-23) and transcription factor levels and obvious decrease in Treg number, Treg related cytokines (IL-10 and TGF-β1) and transcription factor (Foxp3) levels as compared with patients with SA and controls. Results indicate that Th17/Treg functional imbalance exists in patients with ACS, suggesting a potential role for Th17/Treg imbalance in plaque destabilization and the onset of ACS.”

In other words, the inflammatory process of cardiovascular disease that culminates in the rupture of a vulnerable plaque, which is the precipitating event for a heart attack, expresses this Th17/Treg functional imbalance.

Biochemical and Biophysical ResearchYou may have read earlier posts discussing oxidized LDL (ox-LDL) as a fundamental feature of cardiovascular disease and a valuable laboratory marker. This fascinating paper published recently in the journal Biochemical and Biophysical Research Communications that reports on the relationship between ox-LDL and Th17/Treg balance.

Oxidized low-density lipoprotein (ox-LDL) is an instrumental factor in atherogenesis…CD4+CD25+ regulatory T (Treg) cells and Th17 cells, subsets of T-helper cells, play important roles in peripheral immunity and their imbalance leads to the development of tissue inflammation and autoimmune diseases…To explore the shift of Th17/Treg balance in ACS [acute coronary syndrome] patients and the effect of ox-LDL on the balance, we examined the frequencies of Th17 and Treg cells, key transcription factors and relevant cytokines in patients with AMI [acute myocardial infarction = heart attack], UA [unstable angina], stable angina (SA) and controls.”

What did their data show about the connection between these immune cells and inflammatory cardiovascular disease?

“Our study demonstrated that ACS patients have shown a significant increase of Th17 frequency, RORγt expression and serum Interleukin 17 (IL-17), and a obvious decline of Treg frequency, Foxp3 expression, suppressive function, and serum IL-10. Serum ox-LDL positively correlated with the frequency of Th17 cells and negatively correlated with the frequency of Treg cells…. Treg and Th17 cells from ACS patients were significantly more susceptible to ox-LDL-mediated alterations.

Take a moment to appreciate the profound significance of this for the evaluation and treatment of cardiovascular disease. Cholesterol levels can be high in the absence of CVD, but when it is damaged by oxidation it somehow participates in the inflamed lesions of the vessel wall that are the basic characteristic of condition…

“Th17/Treg numerical and functional imbalance exists in ACS patients, and ox-LDL has a direct effect on Th17/Treg imbalance which may contribute to the occurrence of ACS.”

Scandinavian Journal of ImmunologyHow else might Th17/Treg imbalance manifest in cardiovascular disease? A study published this year in the Scandinavian Journal of Immunology reveals its role in idiopathic dilated cardiomyopathy, a fairly common cause of heart failure (the enlarged heart fails to pump properly).

“To assess whether Treg/Th17 balance was broken in patients with idiopathic dilated cardiomyopathy (DCM). We studied 25 patients who were diagnosed as idiopathic DCM (18 men and seven women, mean age 35.6 ± 5.2) and 25 normal persons (18 men and seven women, mean age 33.8 ± 4.9). Then, we detected Treg/Th17 functions on different levels including cell frequencies, related cytokine secretion and key transcription factors in patients with idiopathic DCM and controls.”

What did their data show?

“The results demonstrated that patients with idiopathic DCM revealed significant increase in peripheral Th17 number, Th17-related cytokines (IL-17, IL-6, IL-23) and transcription factor (RORγt) levels and obvious decrease in Treg number, Treg-related cytokines (TGF-β1 and IL-10) and transcription factor (Foxp3) levels when compared to normal persons. Results indicated that Treg/Th17 functional imbalance existed in patients with idiopathic DCM, suggesting a potential role for Treg/Th17 imbalance in the development of idiopathic DCM.”

NephrologyWe can also see that this is a mechanism promoting adverse cardiovascular events when uric acid increases in the bloodstream, such as when people undergo dialysis, from a paper published not long ago in the journal Nephrology.

Adverse cardiovascular events resulting from accelerated atherosclerosis are the leading cause of mortality in uraemic patients on maintenance haemodialysis (MHD). Chronic inflammation due to antigen-specific responses is an important factor in the acceleration of atherosclerosis...The aim of the present study was to assess the Treg/Th17 pattern in uraemic patients on MHD and to explore the significance of Treg/Th17 imbalance in the development and outcome of acute cardiovascular events.”

Their findings offer fascinating insight into the link between uric acid and cardiovascular inflammation:

“Patients with uraemia exhibited an obvious imbalance of Treg/Th17 function when compared to the normal control group, displaying increased peripheral Th17 frequency, Th17-related cytokines (interleukin [IL]-17, IL-6 and IL-23) and RORγt mRNA levels. These patients also displayed decreased Treg frequency, Treg-related cytokines (IL-10, transforming growth factor-β1) and Foxp3 mRNA levels…It was also observed that the imbalance of Treg/Th17 was not only consistent with the cardiovascular disease but also correlated with a microinflammatory state.”

Clinicians and patients should bear their concluding point in mind:

“This Th17/Treg imbalance might act synergistically with microinflammation on immune-mediated atherosclerosis and contribute to the high incidence of adverse cardiovascular events.”

Clinical & Experimental ImmunologyI would like to note the evidence that Th17/Treg imbalance also plays a role in autoimmune disease associated with organ transplantation since a case this year involving autoimmune attack on the nerves regulating the heartbeat followed by another autoimmune inflammatory reaction to the pacemaker (Dressler’s syndrome). The authors of a paper published in Clinical and Experimental Immunology state:

“…it can be proposed that skewing of responses towards Th17 or Th1 and away from Treg may be responsible for the development and/or progression of AD [autoimmune disease] or acute transplant rejection in humans. Blocking critical cytokines in vivo, notably IL-6, may result in a shift from a Th17 towards a regulatory phenotype and induce quiescence of AD or prevent transplant rejection…”

They sum up their extensive review by concluding:

Interleukin 17 is a pleiotropic cytokine with multiple proinflammatory functions that is likely to be involved in either the causation or progression of inflammatory diseases and transplant rejection in humans. Regulatory T cells are an anti-inflammatory lineage of T cells… It is possible that acute flares of autoimmune diseases or acute episodes of transplant rejection may be explained by a change in the relative dominance of these pathways…”

European Journal of ImmunologyWhat resources can we turn to for correcting Th17/Treg imbalances? A fascinating paper just published in the European Journal of Immunology explains how the proinflammatory cytokine IL-6 (Interleukin-6) is a regulator of Th17/Treg.

“IL-6 is a pleiotropic cytokine involved in the physiology of virtually every organ system. Recent studies have demonstrated that IL-6 has a very important role in regulating the balance between IL-17-producing Th17 cells and regulatory T cells (Treg). The two T-cell subsets play prominent roles in immune functions: Th17 cell is a key player in the pathogenesis of autoimmune diseases and protection against bacterial infections, while Treg functions to restrain excessive effector T-cell responses.”

The authors explain the pivotal role played by IL-6 in determining the relative balance of autoimmune inflammation-promoting Th17 versus the anti-inflammatory Treg cells:

“IL-6 induces the development of Th17 cells from naïve T cells together with TGF-β; in contrast, IL-6 inhibits TGF-β-induced Treg differentiation. Dysregulation or overproduction of IL-6 leads to autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA), in which Th17 cells are considered to be the primary cause of pathology.”

Their conclusion offers a welcome insight in that we have evidence-based physiological interventions that act to regulate IL-6:

“Given the critical role of IL-6 in altering the balance between Treg and Th17 cells, controlling IL-6 activities is potentially an effective approach in the treatment of various autoimmune and inflammatory diseases.”

Mucosal ImmunologyFurther evidence for the pivotal role of IL-6 in regulating T17 and Treg balance is found in an interesting paper published in the journal Mucosal Immunology that points out the same process in inflammatory bowel disease:

T helper (Th)17 cells have been shown to play a role in the pathogenesis of inflammatory and autoimmune diseases including inflammatory bowel diseases (IBD). It is now well established that although transforming growth factor (TGF)-beta alone induces FoxP3+ regulatory T (Treg) cells, TGF-beta and interleukin (IL)-6, acting in concert, induce differentiation of mouse naive T cells into Th17.”

Going a step further, they were able to discern that IL-6 can act alone in promoting the development of Th17 cells:

“We found that upon activation, Treg cells induce CD4+CD25- naive T cells or Treg cells themselves to differentiate into Th17 in the presence of IL-6 alone without exogenous addition of TGF-beta.”

Journal of ImmunologyAnother clue to some of the therapies we can use is suggested by a study published in the Journal of Immunology on the ability of retinoic acid (RA), a metabolite of Vitamin A, to inhibit the expression of IL-6. The authors first observe:

“The de novo generation of Foxp3+ regulatory T (Treg) cells in the peripheral immune compartment and the differentiation of Th17 cells both require TGF-β, and IL-6 and IL-21 are switch factors that drive the development of Th17 cells at the expense of Treg cell generation.”

The authors elucidate the pathways by which Treg can be promoted and IL-6 inhibited by retinoic acid (RA):

“Herein we show that RA enhances TGF-β signaling…and this results in increased Foxp3 [Treg] expression even in the presence of IL-6 or IL-21. RA also inhibits the expression of IL-6R{alpha}…and thus inhibits Th17 development. In…experimental autoimmune encephalomyelitis…RA suppresses the disease very efficiently by inhibiting proinflammatory T cell responses, especially pathogenic Th17 responses.”

Their conclusion is well worth keeping in mind when we are researching a treatment plan for the autoimmune component of cardiovascular disease or any other autoimmune condition:

“These data not only identify the signaling mechanisms by which RA can affect both Treg cell and Th17 differentiation, but they also highlight that in vivo during an autoimmune reaction, RA suppresses autoimmunity mainly by inhibiting the generation of effector Th17 cells.”

How important is Vitamin D for autoimmune disease?

Nature Reviews RheumatologyIt’s hard to overemphasize the importance. Consider this paper published in Nature Reviews Rheumatology in which the authors assert that the…

…immunoregulatory and anti-inflammatory properties” of vitamin D can be used for the “control of autoimmune diseases.”

They note that…

“…Epidemiological evidence indicates a significant association between vitamin D deficiency and an increased incidence of several autoimmune diseases,”

Which include…

“a variety…from rheumatoid arthritis to systemic lupus erythematosus, and possibly also multiple sclerosis, type 1 diabetes, inflammatory bowel diseases, and autoimmune prostatitis.”

(Extra highlight for autoimmune prostatitis because very few are aware how common this is.) Of great practical importance is their observation that…

“The net effect of the vitamin D system on the immune response is an enhancement of innate immunity coupled with multifaceted regulation of adaptive immunity.”

PsychoneuroendocrinologyWe are awash in studies on vitamin D, here’s one more for good measure. This paper, recently published in the journal Psychoneuroendocrinology, focuses on its use in the treatment of autoimmune disease that attacks the brain and nervous system. The authors begin by noting that…

“It has been known for more than 20 years that vitamin D exerts marked effects on immune and neural cells…it has been shown that diminished levels of vitamin D…is a risk factor for various brain diseases.”

They further state that…

“…vitamin D has been found to be a strong candidate risk-modifying factor for Multiple Sclerosis (MS)…”

And proceed to..

“…assess how vitamin D imbalance may lay the foundation for a range of adult disorders, including brain pathologies (Parkinson’s disease, epilepsy, depression) and immune-mediated disorders (rheumatoid arthritis, type I diabetes mellitus, systemic lupus erythematosus or inflammatory bowel diseases).”

These are some of the reasons why I always screen for vitamin D sufficiency.

RDW is an inexpensive but powerful indicator often overlooked on your routine blood test

Archives of Internal Medicine 0210RDW stands for Red (Blood Cell) Distribution Width, an index for the degree of variability in the size and shape of your red blood cells. Recent studies are showing it to be a powerful indicator of overall health and the risk of death from multiple causes. RDW is always included in the standard Complete Blood Count (CBC), one of the most routine lab tests in modern medicine, but there’s evidence that the usual lab reference range is too broad and it’s value is not widely appreciated. It has been established for some time that RDW predicts mortality form cardiovascular disease, but this study recently published in the Archives of Internal Medicine is particularly interesting because it shows that RDW predicts mortality in the general population independent of cardiovascular disease. The authors state:

“Higher RDW values were strongly associated with an increased risk of death…Even when analyses were restricted to nonanemic participants or to those in the reference range of RDW (11%-15%) without iron, folate, or vitamin B12 deficiency, RDW remained strongly associated with mortality. The prognostic effect of RDW was observed in both middle-aged and older adults for multiple causes of death.”

Two weeks later the another paper was published in the same journal on the same topic that begins with this observation:

“Red blood cell distribution width (RDW), an automated measure of red blood cell size heterogeneity (eg, anisocytosis) that is largely overlooked, is a newly recognized risk marker in patients with established cardiovascular disease (CVD).”

They set out to investigate

“the association of RDW with all-cause mortality and with CVD, cancer, and chronic lower respiratory tract disease mortality in 15,852 adult participants.”

Their conclusion:

“Higher RDW is associated with increased mortality risk in this large, community-based sample, an association not specific to CVD.”

Journals of GerontologyAnother paper just published in The Journals of Gerontology confirms these findings with an analysis of seven community-based studies of older adults. Their conclusion:

“RDW is a routinely reported test that is a powerful predictor of mortality in community-dwelling older adults with and without age-associated diseases.”

Diabetes Care 0210.2This paper just published in the journal Diabetes Care reports on the link between RDW, metabolic syndrome and cardiovascular disease: “A possible explanation for the observed association between RDW and MetS is that high RDW reflects an underlying inflammatory state that leads to impaired erythrocyte (red blood cell) maturation and anisocytosis (size variation), as suggested previously (1–3). In fact, MetS exacerbates oxidative and inflammatory stress in obese adults, which is a potential mechanism for the increased cardiovascular risk in this condition.”

European Journal of Heart FailureAnd as you would expect, the European Journal of Heart Failure recently published a study on heart failure that compares RDW with N-terminal brain natriuretic peptide (NT-proBNP) in which the authors conclude:

“Red cell distribution width is a readily available test in the HF-population with similar independent prognostic power to NT-proBNP across the first to third quartiles. Prognostic models in HF (heart failure) should include RDW.”

Digestive Diseases and SciencesAnd the ‘plot thickens’. In this paper published in the journal Digestive Diseases and Sciences the investigators observe:

“Impaired iron absorption or increased loss of iron was found to correlate with disease activity and markers of inflammation in inflammatory bowel disease (IBD). Red cell distribution width (RDW) could be a reliable index of anisocytosis with the highest sensitivity to iron deficiency.”

Their compelling conclusion:

“Among the laboratory tests investigated, including fibrinogen, CRP, ESR, and platelet counts…analysis indicated RDW to be the most significant indicator of active UC [ulcerative colitis]. For CD [Crohn's disease], CRP was an important marker of active disease.”

Archives of Pathology & Laboratory MedicineLastly, you’ll appreciate the broadest statement yet about the value of this inexpensive and readily available marker. In a recent paper published in the Archives of Pathology & Laboratory Medicine. The authors begin by chiming in with the neighborhood chorus:

“A strong independent association has been recently observed between elevated red blood cell distribution width (RDW) and increased incidence of cardiovascular events;”

but they aim to

“assess whether RDW is associated with plasma markers of inflammation.”

Their conclusion:

“To our knowledge, our study demonstrates for the first time a strong, graded association of RDW with hsCRP and ESR independent of numerous confounding factors.”

In other words, RDW is inexpensive, easily obtained, and a powerful marker for inflammation in general, the common denominator of most chronic disease.

Here’s the ‘take home’ message (if you’ve gotten this far): If you have almost any blood work done at all it’s likely to include RDW automatically. Make good use of it, keeping in mind that laboratory reference ranges do not reflect the latest research and your doctor may not be aware of this. Functional medicine doctors want RDW to be no more than 13%.

A possible explanation for the observed association between RDW and MetS is that high RDW reflects an underlying inflammatory state that leads to impaired erythrocyte maturation and anisocytosis, as suggested previously (13). In fact, MetS exacerbates oxidative and inflammatory stress in obese adults, which is a potential mechanism for the increased cardiovascular risk in this condition

Adverse events are common with steroids

This meta-analysis of data retrieved from 28 studies comprising 2382 patients was just published in the journal Annals of the Rheumatic Diseases. The important thing to note is that “High rates of adverse events were reported in high-quality studies with short follow-up” for low to medium doses. (All patients received prednisilone.) Rates of adverse events were especially high with inflammatory bowel disease, but significant also for the rheumatic diseases included in the study. This highlights one of the advantages of the functional medicine approach that minimizes dependence on steroids by addressing the underlying immune system dysfunction.

Autism, type 1 diabetes, allergies, asthma and leaky gut in children

This interesting paper published in the journal Acta Pædiatrica discusses the link between disruption of the tight junction barrier of the intestinal lining (leaky gut) and the systemic inflammatory response that is fundamental to type 1 diabetes, inflammatory bowel disease, allergies, asthma and autism in children. Because of the massive presence of immune system tissue in the gut, intestinal barrier integrity is a critical element in the functional medicine approach to these pediatric conditions. We can evaluate allergy, food sensitivity, chronic infection and other factors  with the appropriate laboratory tests and procedures.

Inflammatory Bowel Disease, Interleukin-10 Receptors & Vitamin D

This is one reason why some people need much more Vitamin D than the usual reference level. This paper just published in The New England Journal of Medicine describes the link between inflammatory bowel disease (an autoimmune condition) and mutations affecting the Interleukin-10 receptor. Here’s the connection: IL-10 is an anti-inflammatory cytokine is produced by regulatory T cells. Production of regulatory T cells requires vitamin D. Earlier research has disclosed genetic polymorphisms (variations) in vitamin D receptors; now it’s clear we can also have polymorphisms for IL-10 receptors. Folks, notice how many different diseases have an autoimmune component. Make sure your vitamin D is optimal, not barely adequate.